These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 33278557)

  • 1. Discovery of a multi-target compound for estrogen receptor-positive (ER
    Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
    Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor-positive (ER
    Ferreira Almeida C; Oliveira A; João Ramos M; Fernandes PA; Teixeira N; Amaral C
    Biochem Pharmacol; 2020 Jul; 177():113989. PubMed ID: 32330493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
    Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
    Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
    Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
    Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G
    J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER
    Amaral C; Trouille FM; Almeida CF; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2021 Jun; 210():105876. PubMed ID: 33722705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
    Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated Exposure to 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP), an Active Metabolite of Bisphenol A, Aggressively Stimulates Breast Cancer Cell Growth in an Estrogen Receptor
    Hirao-Suzuki M; Takeda S; Okuda K; Takiguchi M; Yoshihara S
    Mol Pharmacol; 2019 Mar; 95(3):260-268. PubMed ID: 30552153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer.
    Wang B; Ma M; Dai Y; Yu P; Ye L; Wang W; Sha C; Yang H; Yang Y; Zhu Y; Dong L; Wei S; Wang L; Tian J; Wang H
    Eur J Med Chem; 2024 Jan; 264():115934. PubMed ID: 38007911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells.
    Jiang C; Guo J; Wang Z; Xiao B; Lee HJ; Lee EO; Kim SH; Lu J
    Breast Cancer Res; 2007; 9(6):R77. PubMed ID: 17986353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wedelolactone induces growth of breast cancer cells by stimulation of estrogen receptor signalling.
    Nehybova T; Smarda J; Daniel L; Brezovsky J; Benes P
    J Steroid Biochem Mol Biol; 2015 Aug; 152():76-83. PubMed ID: 25934092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP) Targets Estrogen Receptor β, to Evoke the Resistance of Human Breast Cancer MCF-7 Cells to G-1, an Agonist for G Protein-Coupled Estrogen Receptor 1.
    Hirao-Suzuki M; Nagase K; Suemori T; Tsutsumi K; Shigemori E; Tanaka M; Takiguchi M; Sugihara N; Yoshihara S; Takeda S
    Biol Pharm Bull; 2021; 44(10):1524-1529. PubMed ID: 34602561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptors in breast carcinogenesis and endocrine therapy.
    Huang B; Warner M; Gustafsson JÅ
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():240-4. PubMed ID: 25433206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.
    Zhao LM; Jin HS; Liu J; Skaar TC; Ipe J; Lv W; Flockhart DA; Cushman M
    Bioorg Med Chem; 2016 Nov; 24(21):5400-5409. PubMed ID: 27647367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
    Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
    Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
    Lu Y; Liu W
    J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
    Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.